Gene expression data indicate that CASP2 expression is also lower in AML stem cells compared with normal HSCs, and within an AML cohort, low CASP2 expression is associated with poor outcome of AML cases (NCI-Cancer Genome Atlas and BloodSpot databases). Here, CASP2 is linked to acute myeloid leukemia.